In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases (MuTreg)
Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia
About this trial
This is an interventional basic science trial for Autoimmune Diseases focused on measuring Autoimmune Diseases, Inflammation, Graft vs Host Disease, T-lymphocytes, Regulatory, Interleukin-2
Eligibility Criteria
Inclusion Criteria:
- Inclusion criteria common to all patients in different departments:
- Age18 years
- Affiliated to social security or entitled to
- Patient who has been informed of the study and has signed a free and informed consent
Inclusion criteria specific by department:
Inclusion criteria for Clinical Hematology Department:
- Patient with GVHD following allogeneic hematopoietic stem cell transplantation (HSC)
- Or with acquired bone marrow suppression
- Lymphocytosis > 0.5 G/L
Inclusion criteria for Nephrology and Transplantation department:
- Patient with systemic lupus erythematosus (ACR classification criteria)
Inclusion criteria for Neurology department:
- Patient with multiple sclerosis (criteria of Mc Donald 2017)
Inclusion criteria for Rheumatology Department:
- Patient with rheumatoid arthritis (ACR classification criteria)
Inclusion criteria for Internal Medicine-Endocrinology Department:
- Patient with Basedow disease, Hashimoto's thyroiditis
Inclusion criteria for Dermatology Department:
- Patient with vitiligo or alopecia areata or atopic dermatitis
Exclusion Criteria:
Non-inclusion criteria common to all patients:
- Patient under guardianship, curatorship or judicial protection
- Pregnant, parturient or breastfeeding woman
- Patient deprived of liberty
- Patient hospitalized without consent
- Patient admitted to a health or social institution for purposes other than research
- Minor patient
- Adult patient unable to express consent
- Refusal to participate
- Patient on AME
Non-inclusion criteria specific by department:
Non-inclusion criteria for Clinical Hematology Department:
- Ongoing treatment with high doses (>1 mg/kg/d) of systemic corticosteroid therapy
- Ongoing treatment with JAK inhibitors
Non-inclusion criteria for Nephrology and Transplantation Department:
- Ongoing treatment with doses >10 mg/d Prednisone
- Ongoing treatment with Cellcept, Endoxan, Imurel, Belimumab, Anti-CD20, Methotrexate
- Ongoing treatment with JAK inhibitors
Non-inclusion criteria for Neurology Department:
- Treatment with systemic corticosteroid therapy, Fingolimod or Teriflunomide
- Ongoing treatment with JAK inhibitors
- Lymphocytosis < 0.5 G/L
Non-inclusion criteria for Rheumatology Department:
- Ongoing treatment with doses >15 mg/d Prednisone
- Treatment with Rituximab or Tocilizumab
- Ongoing treatment with JAK inhibitors
- Lymphocytosis < 0.5 G/L
Non-inclusion criteria for Internal Medicine - Endocrinology Department:
- Ongoing immunosuppressive therapy
- Ongoing treatment with JAK inhibitors
Non-inclusion criteria for Dermatology Department:
- Ongoing treatment with Methotrexate
- Ongoing treatment with JAK inhibitors
- Ongoing treatment with doses >10 mg/d prednisone